Lipid Goal attainment and prescription behavior in Asian patients with acute coronary syndromes: Experience from a tertiary hospital

Clinical Medicine Insights: Cardiology

Volumn 7, Issue , 2013, Pages 51-57

  Chin, Calvin W ^a   Gao, F ^a   Le, T T ^a   Tan, R S ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

Coronary artery disease; HMG Co A reductase inhibitors; Lipid goal attainment; Secondary prevention

Indexed keywords

EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; ASIAN; DOSE RESPONSE; DRUG DOSE TITRATION; EXPERIENCE; FEMALE; FOLLOW UP; GOAL ATTAINMENT; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TERTIARY HEALTH CARE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 84875195686     PISSN: 11795468     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMC.S11488     Document Type: Article

References (22)

1. De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. delayed conservative simvastatin strategy in patients with acute coronary syndrome: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
2. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipide lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
3. Pedersen TR, Faergeman O, Kastelein JJ, et al. High dose atorvasta- tin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study, a randomized controlled trial. JAMA. 2005; 294:2437-445.
4. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomized trial. Lancet. 2010;376: 1658-1669.
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.
6. Kim HS, Wu YF, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian coun- tries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-ASIA) study. Curr Med Res Opin. 2008;24:1951-1963.
7. Assman G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Effcacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13:776-783.
8. Ho KT, Chin KW, Ng KS, et al. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs. 2006;6:383-391.
9. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005;21:1389-399.
10. Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hyper- cholesterolaemic patients: the CEPHEUS Pan-Asian survery. Eur J Prev Cardiol. 2012;19:781-794.
11. Andrikopoulous G, Tzeis S, Nikas N, et al. Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome-Results from the countrywide TARGET study. Int J Cardiol. 2012; published online instead of print. doi: 10.1016/j.ijcard.2012.10.049.
12. Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Yin DD, Jönsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil. 2005;12:530-534.
13. Lee K, Lee V, Chan WK, et al. Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: Results of the Hong Kong hospital audit study. Value Health. 2008;11:S91-S98.
14. Maron D, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
15. Jones PH, McKenney JM, Karalis DG, et al. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005;149:E1-E8.
16. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of intensive LDL-cholesterol-lowering therapy: A meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376:1670-1681.
17. McKeeny JM, Davidson MH, Saponaro J, et al. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005;46:594-599.
18. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Startified Titration (ACTFAST-1) study. Atherosclerosis. 2007;191: 135-146.
19. Farsang C, Athyros V, Gaw A. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to base- line LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin. 2007;23:1945-56.
20. Ducobu J, Claeys M, Commers K, et al. Efficacy of atorvastatin after LDL- cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. Curr Med Res Opin. 2007;23:1821-1827.
21. [No authors listed]. Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetics patients. Korean J Intern Med. 2008;23:22-29.
22. Ferrer-Garcia JC, Snachez-Ballester E, Albalat-Galera R, Berzosa- Sanchez M, Herrera-Ballester A. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther. 2008;13:183-188.